GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland Sells 10,559 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 10,559 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $96.71, for a total value of $1,021,160.89. Following the transaction, the chief executive officer now directly owns 14,865 shares in the company, valued at $1,437,594.15. This trade represents a 41.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Thursday, March 13th, Katherine Stueland sold 1,078 shares of GeneDx stock. The shares were sold at an average price of $89.44, for a total value of $96,416.32.
• On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The shares were sold at an average price of $94.73, for a total value of $258,707.63.
• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total value of $130,041.36.
• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The stock was sold at an average price of $94.48, for a total value of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The stock was sold at an average price of $78.18, for a total value of $1,407,709.08.

GeneDx Price Performance

Shares of NASDAQ WGS opened at $94.46 on Tuesday. The firm has a market cap of $2.65 billion, a P/E ratio of -48.19 and a beta of 1.91. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a 1-year low of $7.72 and a 1-year high of $115.60. The business’s 50 day moving average is $84.69 and its 200-day moving average is $70.37.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The firm had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. Equities research analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. The Goldman Sachs Group increased their price objective on GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a report on Wednesday, February 19th. TD Cowen raised their price objective on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $72.33.

Hedge Funds Weigh In On GeneDx

A number of hedge funds have recently added to or reduced their stakes in the stock. MCF Advisors LLC increased its stake in shares of GeneDx by 107.7% in the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after purchasing an additional 182 shares during the last quarter. Sterling Capital Management LLC boosted its holdings in shares of GeneDx by 877.8% during the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock valued at $27,000 after acquiring an additional 316 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in shares of GeneDx during the 4th quarter valued at $28,000. Lazard Asset Management LLC acquired a new position in GeneDx during the 4th quarter worth about $35,000. Finally, Comerica Bank acquired a new position in GeneDx during the 4th quarter worth about $50,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.